Latest Insider Transactions at Lexeo Therapeutics, Inc. (LXEO)
This section provides a real-time view of insider transactions for Lexeo Therapeutics, Inc. (LXEO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Lexeo Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Lexeo Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 17
2025
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,133
-2.57%
|
$118,197
$9.25 P/Share
|
|
Oct 17
2025
|
Eric Adler Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,382
-2.21%
|
$30,438
$9.25 P/Share
|
|
Oct 17
2025
|
Jose Manuel Otero Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,115
-1.6%
|
$19,035
$9.25 P/Share
|
|
Oct 17
2025
|
Jenny Robertson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,526
-2.43%
|
$31,734
$9.25 P/Share
|
|
Oct 17
2025
|
Tai Sandi See Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,888
-2.79%
|
$34,992
$9.25 P/Share
|
|
Oct 15
2025
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+11.45%
|
-
|
|
Oct 15
2025
|
Eric Adler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,570
+11.1%
|
-
|
|
Oct 15
2025
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,940
+8.22%
|
-
|
|
Oct 15
2025
|
Jenny Robertson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,900
+12.02%
|
-
|
|
Oct 15
2025
|
Tai Sandi See Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,890
+13.5%
|
-
|
|
Sep 12
2025
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,193
+0.98%
|
$4,386
$2.64 P/Share
|
|
Aug 29
2025
|
Louis Edward Tamayo Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+50.0%
|
-
|
|
Aug 18
2025
|
Jose Manuel Otero Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,848
-4.5%
|
$11,392
$4.67 P/Share
|
|
Aug 18
2025
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,735
-1.23%
|
$10,940
$4.67 P/Share
|
|
Aug 18
2025
|
Eric Adler Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
608
-0.9%
|
$2,432
$4.67 P/Share
|
|
Aug 18
2025
|
Jenny Robertson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
542
-0.86%
|
$2,168
$4.67 P/Share
|
|
Aug 18
2025
|
Tai Sandi See Chief Development Officer |
SELL
Open market or private sale
|
Direct |
382
-0.64%
|
$1,528
$4.67 P/Share
|
|
May 16
2025
|
Tai Sandi See Chief Development Officer |
SELL
Open market or private sale
|
Direct |
367
-0.62%
|
$734
$2.77 P/Share
|
|
May 16
2025
|
Jenny Robertson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
521
-0.82%
|
$1,042
$2.77 P/Share
|
|
May 16
2025
|
Eric Adler Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
585
-0.86%
|
$1,170
$2.77 P/Share
|
|
May 16
2025
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,074
-0.48%
|
$2,148
$2.77 P/Share
|
|
Mar 14
2025
|
Tai Sandi See Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+8.76%
|
$11,440
$2.61 P/Share
|
|
Mar 14
2025
|
Jenny Robertson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+8.25%
|
$11,440
$2.61 P/Share
|
|
Mar 14
2025
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+8.3%
|
$11,440
$2.61 P/Share
|
|
Mar 14
2025
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,128
+0.95%
|
$4,256
$2.61 P/Share
|
|
Feb 19
2025
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,326
-1.93%
|
$17,304
$4.41 P/Share
|
|
Feb 19
2025
|
Jenny Robertson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,101
-3.5%
|
$8,404
$4.41 P/Share
|
|
Feb 19
2025
|
Eric Adler Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,359
-3.34%
|
$9,436
$4.41 P/Share
|
|
Feb 19
2025
|
Tai Sandi See Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,486
-2.68%
|
$5,944
$4.41 P/Share
|
|
Jan 17
2025
|
Kyle Rasbach Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,875
+50.0%
|
-
|
|
Jan 07
2025
|
Eric Adler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+38.25%
|
-
|
|
Jan 07
2025
|
Tai Sandi See Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,750
+41.17%
|
-
|
|
Jan 07
2025
|
Jenny Robertson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,250
+37.66%
|
-
|
|
Jan 07
2025
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+31.34%
|
-
|
|
Jan 07
2025
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
103,750
+31.61%
|
-
|
|
Dec 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.03%
|
$20,000
$8.2 P/Share
|
|
Dec 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.99%
|
$5,000
$2.33 P/Share
|
|
Nov 25
2024
|
Paula H Cholmondeley |
BUY
Open market or private purchase
|
Direct |
15,000
+32.88%
|
$90,000
$6.99 P/Share
|
|
Nov 11
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.03%
|
$17,500
$7.82 P/Share
|
|
Nov 11
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.99%
|
$5,000
$2.33 P/Share
|
|
Oct 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$40,000
$8.1 P/Share
|
|
Oct 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Sep 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$50,000
$10.65 P/Share
|
|
Sep 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Aug 12
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$55,000
$11.53 P/Share
|
|
Aug 12
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Jul 11
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,031
-9.43%
|
$504,558
$18.06 P/Share
|
|
Jul 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,969
-7.82%
|
$431,504
$16.65 P/Share
|
|
Jul 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.77%
|
$10,000
$2.33 P/Share
|
|
Jun 12
2024
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+50.0%
|
-
|